Table 2.
Expression of hsv1-miR-H18 and hsv2-miR-H9-5p in prostate cancer
| Variable | No. of patients | hsv1-miR-H18 level (× 103 copies/miRNA concentration) | P-value | hsv2-miR-H9-5p level (× 103 copies/miRNA concentration) | P-value |
|---|---|---|---|---|---|
| Age (yr) | 0.495 | 0.412 | |||
| < 70 | 101 | 280.4 (58.8–4064.8) | 38.3 (14.5–136.8) | ||
| ≥ 70 | 91 | 293.6 (45.2–2043.7) | 31.0 (15.0–114.2) | ||
| PSA (ng/mL) | 0.465 | 0.079 | |||
| < 10 | 78 | 355.0 (53.5–3913.2) | 49.8 (17.6–142.0) | ||
| ≥ 10 | 114 | 255.5 (45.9–2374.4) | 31.1 (12.5–113.7) | ||
| Gleason score | 0.297 | 0.195 | |||
| ≤7 | 103 | 295.0 (62.8–4685.8) | 39.3 (16.3–136.3) | ||
| ≥8 | 89 | 286.1 (38.8–2429.6) | 28.1 (12.7–110.4) | ||
| Stage | 0.198 | 0.241 | |||
| T3 or less | 126 | 305.0 (60.0–3290.7) | 35.3 (16.8–135.1) | ||
| T4 or metastatic | 66 | 257.0 (35.0–1721.1) | 30.4 (11.2–104.2) |
Values are presented as median (interquartile range).
PSA, prostate-specific antigen.
The Mann-Whitney U-test was used to compare expression levels and clinical variables.